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Abstract We provide the first evidence that point mutations can
constitutively activate the L1-adrenergic receptor (AR). Leucine
322 of the L1-AR in the C-terminal portion of its third
intracellular loop was replaced with seven amino acids (I, T, E,
F, C, A and K) differing in their physico-chemical properties. The
L1-AR mutants expressed in HEK-293 cells displayed various
levels of constitutive activity which could be partially inhibited by
some beta-blockers. The results of this study might have
interesting implications for future studies aiming at elucidating
the activation process of the L1-AR as well as the mechanism of
action of beta-blockers.
z 1999 Federation of European Biochemical Societies.
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1. Introduction
The adrenergic receptors (AR) mediate the functional ef-
fects of epinephrine and norepinephrine by coupling to several
of the major signalling pathways modulated by G proteins.
The AR family includes nine di¡erent gene products: three L
(L1, L2, L3), three K2 (K2A, K2B, K2C) and three K1 (K1a, K1b,
K1d) receptor subtypes. Like all G protein-coupled receptors
(GPCR), the ARs display seven transmembrane K-helices
which contribute to form the ligand binding pocket, whereas
amino acid sequences of the intracellular (i) loops mediate the
interaction of the receptor with the G protein as well as with
other signalling and regulatory factors [1].
We have previously reported that mutations of alanine 293
in the C-terminal portion of the 3i loop of the K1b-AR could
dramatically increase the constitutive activity of the receptor
[2]. A constitutively active mutant of the L2-AR (L2-CAM)
was constructed by mutating four residues in the C-terminal
portion of its third intracellular loop including leucine 272
which is homologous to alanine 293 in the K1b-AR [3]. The
constitutive activity of the K2A-AR could be increased by dif-
ferent mutations of the single residue threonine 348 corre-
sponding to alanine 293 in the K1b-AR [4]. Activating muta-
tions in the C-terminal portion of the 3i loop have also been
described for several other GPCRs [5].
The availability of both constitutively active GPCR mu-
tants and cell systems overexpressing wild type GPCR has
presented a useful tool to identify inverse agonists (or negative
antagonists) which exhibit the de¢ning property of inhibiting
the agonist-independent activity of the receptors [6]. In par-
ticular, it has been previously demonstrated that several clas-
sical beta-blockers can behave either as partial agonists, neu-
tral antagonists or inverse agonists in cells expressing the wild
type L2-AR or at the L2-CAM [7,8].
The main aim of this study was to investigate whether mu-
tations in the C-terminal portion of the third intracellular
loop could activate the L1-AR for which constitutively active
mutants have not been described so far. To achieve this goal,
leucine 322 of the L1-AR (homologous to alanine 293 of the
K1b-AR, threonine 368 of the K2A-AR and leucine 272 of the
L2-AR) was replaced with seven amino acids di¡ering in their
physico-chemical properties and the receptor mutants were
tested for their ability to mediate agonist-independent accu-
mulation of cAMP. Our study provides the ¢rst evidence that
the L1-AR can be activated by point mutations and might
contribute to further elucidate the pharmacological e¡ects of
drugs acting at di¡erent L-AR subtypes.
2. Materials and methods
2.1. Drugs
Ligands were purchased from TOCRIS ((+) or (3)propranolol,
timolol, betaxolol, ICI118,551, practolol, sotalol), Sigma (alprenolol,
( þ )propranolol, labetolol, metoprolol), RBI (CGP20712A) and Al-
drich (atenolol). Carvedilol was a gift from P¢zer.
2.2. Mutagenesis and cell transfection
The cDNA encoding the human L1-AR [9] was mutated by PCR-
mediated mutagenesis technique using Taq DNA polymerase (Roche).
The mutated DNA fragments obtained were digested with the appro-
priate enzymes and cloned into the expression vector pRK-5 contain-
ing the wild type L1-AR cDNA. The cDNAs encoding the wild type
human L2-AR or the constitutively active L2-CAM [3] were also in the
expression vector pRK-5. HEK-293 cells, grown in DMEM Nut Mix
F-12 (Gibco BRL) supplemented with 10% FCS and gentamicin (100
Wg/ml), were transiently transfected with di¡erent cDNAs using the
FuGENE 6 transfection reagent (Boehringer Mannheim) and har-
vested 48 h after the transfection. The transfected DNA was 0.5^
1 Wg/106 cells.
2.3. Ligand binding
Crude membranes were prepared from cells expressing the L-ARs
and their mutants. The binding was performed at 25‡C in 50 mM
Tris-HCl (pH 7.4), 150 mM NaCl and 5 mM EDTA. For saturation
binding experiments of [125I]CYP (DuPont-NEN, Boston, MA), the
radioligand concentration ranged from 12 to 400 pM and 1036 M
alprenolol was used to determine non-speci¢c binding. In competition
binding experiments, the ¢nal concentrations of [125I]CYP was 80 pM.
Results of ligand binding experiments were analyzed using Prism 2.0
(GraphPAD, Software, San Diego, CA, USA).
2.4. cAMP measurements
Cells were transfected in 6-well dishes and incubated overnight in
culture medium containing 2.5 WCi/ml [3H]adenine (Amersham) with
5% fetal calf serum (FCS). After removal of the radioactive medium,
the cells were incubated in culture medium without serum containing
10 mM HEPES and 1 mM isobutylmethylxanthine in the presence or
absence of di¡erent ligands for 30 min. The medium was then re-
moved and the cells were lysed in 1 ml of 2.5% perchloric acid. The
[3H]cAMP content of the cell lysate was determined as previously
described by chromatography on Dowex/alumina columns [4].
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2.5. Statistical analysis
Statistical analysis was performed as indicated in the ¢gure legends
using Prism 2.0 (GraphPAD, Software, San Diego, CA, USA).
3. Results
3.1. Activating mutations of the L1-AR
Leucine 322 in the C-terminal portion of the 3i loop of the
L1-AR was mutated into seven amino acids di¡ering in their
physico-chemical properties. The wild type L1-AR and its mu-
tants (L322I, L322T, L322E, L322F, L322C, L322A and
L322K) were expressed in HEK-293. The properties of the
L1-ARs were compared with those of the wild type L2-AR
and of its constitutively active mutant L2-CAM [3] carrying
four mutations in the C-terminal portion of the 3i loop of the
receptor including the mutation of leucine 272 homologous to
leucine 322 of the L1-AR.
Cells expressing the various receptors did not display sig-
ni¢cant di¡erences in the total incorporation of [3H]adenine
which was about 0.05%. On the other hand, clear di¡erences
were observed in the basal levels of cAMP in cells expressing
the various receptors (Fig. 1). In cells expressing the wild type
L1-AR or L2-AR the basal levels of cAMP were 90% higher
than in control cells expressing the vector alone (cAMP was
166 þ 20 cpm/well for the vector alone, 316 þ 35* cpm/well for
L1-AR and 384 þ 38* for L2-AR, mean þ S.E.M. of six experi-
ments, *P6 0.05 compared to vector alone). Thus both the
wild type L1-AR and L2-AR display a very small, but signi¢-
cant spontaneous activity.
In agreement with previous ¢ndings in COS-7 cells [3], ex-
pression of the L2-CAM in HEK-293 cells resulted in a sig-
ni¢cant 2.7-fold increase of the basal cAMP accumulation as
compared to cells expressing the wild type L2-AR (Fig. 1). For
L322I, L322T and L322E the agonist-independent activity
was not signi¢cantly di¡erent from that of the wild type L1-
Fig. 1. Basal cAMP response in cells expressing the wild type and
mutated L1- and L2-AR subtypes. [3H]cAMP accumulation was
measured in HEK-293 cells expressing the wild type or mutated re-
ceptors as described in Section 2. The L1-AR mutants carried muta-
tions of leucine 322. The L2-CAM carried four mutations in the 3i
loop of the receptor as previously described [3]. Receptor expression
ranged between 2.5 and 3 pmol/mg of protein for the L1-ARs and
1 and 2 pmol/mg of protein for the L2-ARs. Results are the
mean þ S.E.M. of seven independent experiments. Statistical signi¢-
cance was analyzed by unpaired Student’s t-test, *P6 0.05. Basal of
the mutants was compared to that of their respective wild type re-
ceptor. T
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AR. In contrast, for the other mutants the basal activity was
3^9-fold greater (L322F6L322C6L322A6L322K) than
that of the wild type L1-AR (Fig. 1). The L322A and
L322K mutants displayed a constitutive activity much greater
than that observed for L2-CAM.
These results demonstrate that mutations of leucine 322 can
constitutively activate L1-AR supporting the notion that the
C-terminal portion of the 3i loop is an important switch reg-
ulating the activation of many GPCRs [1].
3.2. E¡ect of di¡erent ligands on receptor-mediated cAMP
accumulation
As shown in Table 1, stimulation of the wild type L1-AR
and L2-AR with isoproterenol or epinephrine resulted in a
large increase of cAMP accumulation which was similar for
the two receptors. Stimulation of cells with agonists could also
increase the cAMP response mediated by L2-CAM and by the
L1-AR mutants. The maximal cAMP levels induced by iso-
proterenol for the wild type L-ARs and their mutants ranged
between 15 000 to 25 000 cpm/well. However, the cAMP in-
crease expressed as fold of basal was smaller for the L322F,
L322C, L322A, L322K and L2-CAM as compared to the wild
type receptors because of their increased constitutive activity
(Table 1).
Fig. 2 shows the e¡ect of di¡erent beta-blockers on the
response mediated by the wild type L1-AR and L2-AR or by
their respective most active mutants, L322K and L2-CAM.
Several beta-blockers displayed partial agonist activity at
both the wild type receptors and their constitutively active
mutants. However, their partial agonism was very small as
compared to the e¡ect of isoproterenol, as shown in Table
1. The non-selective blockers alprenolol, carvedilol, labetalol,
(+) and (3)propranolol and the L1-selective practolol behaved
as weak partial agonists at both the L1 and L2-ARs (Fig. 2).
Timolol displayed weak partial agonism at the L1-ARs and
neutral antagonism at the L2-ARs. Vice versa, sotalol was a
very weak partial agonist at the the L2-ARs, being neutral at
the L1-ARs.
A set of three beta-blockers, i.e. the L1-selective betaxolol
and CGP20712A and the L2-selective ICI118,551, displayed
some di¡erences at the constitutively active L322K and L2-
CAM. All three compounds were partial inverse agonists at
the L322K. In contrast, the basal activity of L2-CAM could be
partially inhibited only by betaxolol and ICI118,551,
CGP20712A being neutral (Fig. 2). Inverse agonism at the
wild type receptors was di⁄cult to assess because of their
low spontaneous activity.
The e¡ects of various ligands observed at the L322K mu-
tant were conserved at the other receptor mutants carrying
di¡erent mutations of L322 (Table 1). In particular, betaxolol,
CGP20712A, and ICI118,551 could also partially inhibit the
basal activity of the other constitutively active mutants
L322F, L322C and L322A.
3.3. Ligand binding a⁄nity for the wild type L1-AR and
mutated receptors
The allosteric ternary complex model of receptor activation
[3] predicts that constitutively active receptor mutants display
increased a⁄nity for agonists and decreased a⁄nity for in-
verse agonists as compared to wild type GPCRs whereas the
a⁄nity of neutral antagonists should be similar [8]. To test
this hypothesis, the a⁄nity of the agonists, isoproterenol and
epinephrine, as well as of most beta-blockers was measured in
membranes derived from HEK-293 cells expressing the wild
type L1-AR or its mutants (Table 2).
In agreement with the predictions of the allosteric ternary
complex model [3], the a⁄nity of isoproterenol and epineph-
rine was increased at the receptor mutants in a manner which
was, at large extent, related to their constitutive activity. In
fact the Ki values of isoproterenol and epinephrine at the most
active mutant, L322K, were 200- and 100-fold smaller, respec-
tively, as compared to those at the wild type L1-AR (Table 2).
The L322F, L322C and L322A mutants characterized by an
intermediate level of constitutive activity displayed a 10-fold
increase of their a⁄nities for both isoproterenol and epineph-
rine. The L322E mutant was also characterized by a 10-fold
increase of a⁄nity for both agonists despite the fact that the
small increase of its constitutive activity as compared to that
of the wild type receptor was not signi¢cant. As previously
reported, the a⁄nity of isoproterenol for L2-CAM was 25-fold
greater than that for the wild type L2-AR (results not shown).
In contrast, the Ki values of all the beta-blockers tested
Table 2
Ligand binding a⁄nity for the wild type L1-AR and its mutants carrying mutations of L322
Ligand L1-AR L322I L322T L322E L322F L322C L322A L322K
Isoproterenol 6.55 6.33 6.96 7.43 7.39 7.23 7.52 8.46
(3)Epinephrine 4.84 4.68 5.44 5.84 5.61 5.55 5.9 7.15
(3)Alprenolol 8.17 8.21 8.18 8.41 8.24 8.18 8.29 8.31
Labetalol 7.13 7.12 7.26 7.76 7.24 7.19 7.32 7.08
(+)Propranolol 6.36 6.29 6.33 6.51 6.30 6.25 6.35 6.40
(3)Propranolol 8.47 8.52 8.67 8.81 8.84 8.72 8.65 8.78
( þ )Propranolol 8.22 8.47 8.58 8.48 8.46 8.40 8.35 8.49
Sotalol 5.28 5.39 5.72 5.53 5.66 5.57 5.65 5.54
(3)Timolol 8.19 8.33 8.29 8.29 8.22 8.12 8.67 8.91
Atenolol 6.26 6.43 6.52 6.69 6.77 6.78 6.59 6.58
Betaxolol 7.80 7.66 8.08 8.08 8.07 7.88 8.07 8.06
CGP20712A 7.69 7.86 8.05 8.02 8.06 7.93 8.12 8.04
( þ )Metoprolol 6.74 6.69 7.05 7.17 7.04 6.98 7.16 7.18
Practolol 5.77 5.58 5.94 5.91 5.89 5.86 6.00 6.16
ICI118,551 6.15 5.99 6.15 6.06 6.09 6.05 6.25 6.19
The a⁄nities expressed as pKi were determined in competition binding experiments using [125I]CYP in cell membranes as described in Section
2. The best ¢t of the competition curves was monophasic and the Hill coe⁄cient ranged between 0.7 and 1. The results for the mutants are the
mean of two experiments which did not di¡er by more than 40%. The results for the wild type receptor are the mean of three or four experi-
ments.
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were not di¡erent at the mutants as compared to the wild type
L1-AR (Table 2). Similarly, the Kd of [125I]CYP was about 80
pM for all the receptors (results not shown). These results are
not surprising and can ¢nd their interpretation in the frame-
work of the allosteric ternary complex model [8]. As predicted
by the relationship between the di¡erence in ligand a⁄nity
between the CAM versus the wild type receptor and the iso-
merization constant J of the receptor, the change of a⁄nity
induced by an activating mutation can be much larger for full
agonists than for inverse agonists depending on the value of J
[8]. For example, the a⁄nity of isoproterenol for L2-CAM was
25-fold higher, whereas that of the full inverse agonist
ICI118,551 was only 2-fold lower than for the wild type re-
ceptor.
4. Discussion
The main ¢nding of our study is that point mutations can
constitutively activate the L1-AR for which activating muta-
tions had not been described before. Several studies have fo-
cused so far on the L2-AR whereas much less is known about
the structure-relationship activity of the L1-AR. It has been
reported that the e⁄cacy of coupling to Gs of the L1-AR is
lower than that of the L2-AR in Ltk3 mouse ¢broblasts [10].
This was mainly demonstrated by the fact that the L1-AR-
mediated cAMP response was smaller than that elicited by
equivalent densities of L2-AR. In our study, the maximal ag-
onist-induced response was similar for the two receptors, in
agreement with the results obtained in another study compar-
ing the receptors in CHW mouse ¢broblasts [11]. In addition,
the constitutive activity induced by some mutations of L322
was higher than that of the L2-CAM. Altogether, these results
demonstrate that in HEK-293 cells the L1-AR can be at least
as active as the L2-AR.
Our ¢ndings on the e¡ect of beta-blockers on the constitu-
tive activity of the L2-CAM are in agreement with those from
a previous study demonstrating that among the ligands tested
only betaxolol and ICI118,551 could inhibit the agonist-inde-
pendent activity of L2-CAM measured in membranes derived
from CHO cells permanently expressing the receptor [3]. In
Fig. 2. E¡ects of di¡erent beta-blockers on the basal cAMP response mediated by the L1- and L2-AR subtypes and their constitutively active
mutants. [3H]cAMP accumulation was measured in HEK-293 cells expressing the wild type or mutated receptors as described in Section 2 in
the absence (basal) or presence of di¡erent ligands. The ¢nal concentration of the ligands was as indicated in Table 1. The ligands are grouped
according to their selectivity: non-selective (light stippling), L1-selective (medium stippling) and L2-selective (dark stippling). Results are the
mean þ S.E.M. of three independent experiments. Statistical signi¢cance was analyzed by unpaired Student’s t-test on the inhibition of basal:
P6 0.05 (ligand versus basal) for ICI118,551 at L322K, wild type L2-AR and L2-CAM; for betaxolol at L322K and L2-CAM; for CGP20712A
at L322K.
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transgenic mice overexpressing the wild type L2-AR,
ICI118,551 also behaved as an inverse agonist inhibiting the
agonist-independent myocardial activity [12]. However, the
results of other studies investigating inverse agonism at the
L2-AR or its CAM are apparently divergent. In NG108-15
cells overexpressing L2-CAM [13] not only betaxolol and
ICI118,551 but also timolol and sotalol (which are very
weak partial agonists in our study) behaved as inverse ago-
nists on the receptor-mediated activation of adenylyl cyclase
in membranes. In the study by Chidiac et al. in membranes
derived from Sf9 cells overexpressing wild type L2-CAM [7],
most ligands tested displayed di¡erent degrees of inverse
agonism according the following rank order timolols propra-
nolols alprenolols pindolols labetalols dichloroisoprotere-
nol. Betaxolol and ICI118,551 were not tested in this study.
Interestingly, this study reported that the degree of negative
e⁄cacy of propranolol was positively correlated with receptor
expression. In addition, whereas in membranes most ligands
behaved as partial inverse agonists, in whole cells most of
them were weak partial agonists in agreement with our
present results. In another interesting study it was reported
that receptor desensitization as well as the initial state of the
receptor can modulate the degree of negative e⁄cacy of beta-
blockers at the L2-AR expressed in Sf9 cells [14].
On the basis of all these ¢ndings one might conclude that
those beta-blockers with marked negative e⁄cacy, i.e. betax-
olol and ICI118,551, unequivocally display inverse agonism at
the L2-AR or its CAM under di¡erent experimental condi-
tions. In contrast, other beta-blockers can display modest in-
verse agonism or partial agonism depending on the experi-
mental conditions under which they have been tested, e.g.
cell system expressing the receptor, levels of receptor expres-
sion, measurement of cAMP production in membranes versus
whole cells, desensitization state of the receptor system.
Inverse agonism at the recombinant L1-AR has not been
reported before. However, the e¡ect of some beta-blockers
has been investigated in a physiological system on the re-
sponse mediated by the L1-AR in isolated guinea pig and
human cardiomyocytes [15]. Interestingly, in this cell system
the agonist-independent activation of calcium currents in-
duced by the L1-AR could be partially inhibited by atenolol
and propranolol. ICI118,551 did not have any e¡ect in the
guinea pig cardiomyocytes, but it was not tested on the hu-
man cells. Inverse agonism was more pronounced in the pres-
ence of forskolin which sensitizes the cAMP-dependent calci-
um response. These ¢ndings di¡er from those of our present
study in which atenolol and propranolol display some partial
agonism at the recombinant human L1-AR and its CAMs. As
discussed before, the e¡ect of beta-blockers on the spontane-
ous activity of either the L1- or L2-AR subtypes might depend
to a large extent on the experimental system investigated.
In conclusion, the experimental results available so far do
not support a general classi¢cation of beta-blockers based on
their pharmacological properties at the L1- or L2-AR sub-
types, i.e. neutral antagonism, inverse agonism and partial
agonism. As a consequence, the correlation between the in
vivo e¡ects of beta-blockers and their pharmacological prop-
erties as well as the clinical signi¢cance of inverse agonism
remain to be further explored. In this respect, the constitu-
tively active L1-AR mutants described in this work might
represent a new useful tool to further investigate, on one
hand, the activation process of the L1-AR and, on the other,
the mechanism of action of beta-blockers.
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